Bax is an important protein involved in apoptotic process. Mutations of the Bax gene are known to affect protein expression and function. A promotor polymorphism G(−248)A in the 5' UTR of Bax gene may alter regulation of apoptosis in carcinogenesis. Our study was performed to test the association between G(−248)A polymorphisms in the Bax gene and breast cancer risk and progression. G(−248)A polymorphism was genotyped in a Turkish breast cancer, case-control population including 53 female cancer patients (mean age ± SD: 60.9 ± 11.9 years) and 82 controls (mean age ± SD: 57.2 ± 17.5 years) using PCR-RFLP analysis. Genotype and allele frequencies were assessed with the chi-square test. There was no difference in the distribution of Bax genotypes, and allele frequencies were G (87.7% versus 88.4%) and A (12.3% versus 11.6%) in the cancer patients and controls, respectively. Within the cancer group, the presence of a polymorphic Bax G(−248)A allele was not associated with clinico-pathological parameters such as advanced tumor stage, lymph node or distant metastasis. We present the first to report on Bax G(−248)A polymorphisms in breast cancer. Our results suggest that Bax G(−248)A polymorphism do not modify individual susceptibility to invasive breast cancer in Turkish women.
INTRODUCTION
Breast cancer is the most frequent and lethal cancer among the women all around the world. According to statistics 226,870 women will be diagnosed as breast cancer and 39,510 deaths will be reported relevant to the disease in the US by 2012 [1] . A variety of factors play role in disease progression. Although heredity plays an important role in carcinogenesis, environmental factors, nutrition habits and somatic mutations also increase the possibility of the disease. Early diagnosis, which is specifically important for prolonged survival of the patients, has a great importance also in breast cancer as well as all other cancer types. Gene polymorphisms are known to be cancer risk detection parameters and a variety of genes which are related to increased cell proliferation and lost of apoptosis are being investigated worldwide. As all other cancers, altered apoptosis regulation is one of the major problems in breast cancer. Apoptosis in breast cancer has two different pathways. The first pathway is known as extrinsic pathway, and it is initiated by the death receptors which are the sub group of TNF receptor family [2] . In our earlier studies, we demonstrated the connection between breast cancer and polymorphisms of TNF related apoptosis inducing ligand (TRAIL) [3] . The second pathway is mitochondria centered and known as the intrinsic pathway. Regulation of this pathway is carried out by Bcl-2 family proteins that control the mitochondrial release of death factors such as cytochrome c, AIF, Smac/DIABLO and endonuclease C [4] [5] [6] [7] . BAX (Bcl-2 associated × protein) protein is one of the proapoptotic members of Bcl-2 family and in vivo studies in animal models and cancer cell lines demonstrate that it induces the apoptosis as a tumor suppressor [8] . Bax gene is the first defined apoptotic gene that directly activated by p53 [9] . This direct regulation puts a spotlight on Bax gene especially for understanding the mechanism underlying the carcinogenesis process and possible treatment approaches.
Bax gene is located in chromosome 19q13.3 and mutations in the promoter and coding region of it are known to alter the protein expression and function thus, affecting the ability of apoptosis [10] . 50% of human colon adenocarcinomas with the microsatellite mutator phenoltype and 20% of human hematopoetic malignancies were found to harbor Bax mutations [11, 12] .
Bax protein has Bcl-2 homologous domains (BH1, BH2, BH3 and pseudo BH4) as other Bcl-2 family members. Among these conserved domains, BH3 is the most important one in the protein functions since it is known to be essential in both hetero-and homo dimerization proses and pro apoptotic ability [13] [14] [15] .
Alterations [11, 12, [16] [17] [18] [19] .
In a similar aspect Bax mutations are seem to be infrequent in AIDS-NHL (Non-Hodgkin's Lymphomas) and deregulated apoptosis is not caused by Bax mutations [20] . In addition studies indicating the role of Bax mutations in cancer with microsatellite instability including colorectal cancers [21, 22] and gastric carcinomas [23, 24] . Aframeshift mutation of the Bax gene in basal cell carcinoma was reported in Korean patients [25] . Beside to structural, thus functional, effects; alterations in Bax protein expression are other consequence of the mutations in Bax gene. Altered Bax protein expression has been observed in a variety of cancer [26] .
Poor clinical outcome in breast carcinoma [27] , nonHodgkin lymphoma [28] , ovarian [29] and colon cancer [11] is shown to be related with reduced Bax expression.
Thus, mutations in the promotor region of the Bax gene are specifically taking attention. A guanine adenine substitution in 248 nucleotides upstream from the translation start point of the Bax is reported to be relevant with different conditions in different cancer types. Relation of this SNP with treatment resistance and shorter survival in chronic lymphocytic leukemia was reported [30] . In another study, G(−248)A change was shown to reduce the gene expression [31] Influence of G(−248)A SNP in chronic lymhocytic leukemia Binet stage was also identified [32] . In a more recent research, the effect of a single nucleotide polymorphism in the bax gene promoter in transcription and cell death in retinal ganglion cells was shown in knockout mice [33] . Influence of Bax in the therapy response is also investigated in the expression levels. It was indicated that bax has the second largest influence on intrinsic cisplatin sensivity after Bcl-2 [34] . This promotor SNP has another possible importance in means of defining risk factors in cancer prediction. An elevated risk of squamous cell carcinoma of head and neck in patients having AA genotype of G(−248)A SNP was reported [10] .
Taken together, these data suggest a key role of Bax in carcinogenesis, direct effect of the G(−248)A promoter polymorphism is still controversial. Regarding the lack of a study in this matter, we aimed to investigate G(−248)A polymorphism in breast cancer.
MATERIALS AND METHODS

Study Subjects
Fifty-three breast cancer patients (mean age 60.9 ± 11.9 years) and 82 healthy females (mean age 57.2 ± 17.5 years) were collected between 2007 and 2011 for the study. All participants provided written informed constant prior to study. Subjects were provided from Istanbul Research and Education Hospital, Surgery Clinic and Istanbul Oncology Institute, Radiation Oncology Department. A standardized questionnaire, pathological records and medical records were received to confirm the diagnosis and cancer status. The control subjects, which were not taking any regular medication by that time, were randomly selected among volunteers. The blood samples were collected after pathological diagnosis and prior to any chemotherapeutic or radiation therapy from those patients who had not undergone blood transfusion. The study was approved by the Medical Ethics Committee of Istanbul Medical Faculty.
Methods
Blood sampled were collected into EDTA containing tubes. DNA was isolated from White blood cells by salting out procedure; ammonium acetate extraction and ethanol precipitation fallowing sodium dodecyl sulphatelysis and proteinase K digestion [35] .
Promotor region of the Bax gene was amplified by using 10 pmol forward (5'-CGG GGT TAT CTC TTG GGC-3') and reverse (5'-GTG AGA GCC CCG CTG AAC-3') primers. The PCR reaction mixture contained 150 ng DNA template, 15 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl (pH 8.4), 200 µM each od deoxynucleotide triphosphate (MBI Fermentase, Vilnius, Lithuania) and 2 units of Taq DNA polymerase (MBI Fermentase, Vilnius, Lithuania). The DNA was denaturated at 95˚C for 5 minutes and temperature cycling was set at 94˚C for 30 seconds, 56˚C for 30 seconds, and 72˚C for 45 seconds for 40 cycles, followed by a final extension at 72˚C for 5 minutes.
438 bp PCR products were digested by AciI (MBI Fermentase, Vilnius, Lithuania) enzyme as manufacturer instructions. After AciI digestion, we detected two fragments having 256 and 96 bp (GG) or three fragments having 352, 256 and 96 bp (GA). Digestion of AA genotype creates a 352 bp fragment which we did not observe.
Digestion products were visualized under ultraviolet light and a photo was taken with a Polaroid camera. In case of and doubt concerning the allele, the sample was analyzed once again.
Statistical analyses were carried out using SPSS version 7.5 For Windows (SPSS Inc, Chicago, USA). Numeric values were analyzed by Student's t-test. Differences in characteristics between breast cancer patients and controls, as well as disparities in genotype and allele frequencies, were assessed with the chi-square test. Odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated to estimate the risk of breast cancer. pvalues more than 0.05 were considered statistically insignificant.
RESULTS
We determined Bax G(−248)A polymorphism in 53 breast cancer patients and 82 controls (Figure 1) . Table 1 shows the demographic and clinicopathologic data of our patients groups.
Genotypes and allele frequencies for Bax G(−248)A in breast cancer patients and controls are listed in Table 2 Table 3 . Among breast cancer patients, there were no significant association between the Bax G(−248)A genotypes and some clinical parameters including age at diagnosis, family history, menopausal status, smoking, using alcohol and some pathological parameters such as tumor stage, lymph node metastasis, distant metastasis, periganglionar invasion, estrogen and progesterone receptor status and also tumor differentiation (data are not shown).
DISCUSSION
Bax gene which is a member of Bcl-2 family is an important regulator of apoptosis. Although altered expression of Bax protein seems to be more relevant with carcinogenesis process, mutations leading this disregulation and correlations of these mutations with different cancers are hotspots among the researchers. Promotor region of the Bax gene contains p53 response elements thus affects gene expression [31] . In control group, genotypic frequencies were 94.3% and 5.7% for GG and GA genotypes; and allelic frequencies were 0.97 and 0.03 for G and A alleles respectively. Although the differences in distribution of alleles; absence of AA genotype neither in control nor in patient group, supports our findings.
In a more recent study, Skogsberg et al. used a bigger study group (463 cases and 207 controls) and found no significant differences between Bax G(−248)A polymerphism and CLL progression or treatment resistant [36] . Genotyping frequencies in control group were 79%, 19% and 2% for GG, GA and AA genotypes respectively, again indicating a rare presence of A allele. These results are highly relevant to our findings (76.8% GG, 23.2% GA, 0% AA; n = 82) if we consider the number of subjects that has been examined. It is possible to get more similar results with a higher number of subject.
In this study, we did not record a statistically significant difference in Bax G(−248)A genotype and allele frequencies between breast cancer patients and control. However we observed that some of the clinic-pathological data may be related with specific genotypes.
GG genotype frequency (83.9%) was higher in patients with angiolymphatic invasion when compared to those without (63.6%). These results suggest that GG genotype in the Bax promoter region may increase angiolymphatic invasion in breast cancer and consequently increase metastatic spread and be an adverse prognostic factor.
A similar relationship was also observed in patients carrying the Bax AG genotype, with 1.79 fold increased risk for capsule invasion. Capsular invasion at metastatic nodes in breast cancer was shown to be strongly associated with further regional nodes metastasis [37, 38] . Thus, such a possible increased risk may be related to breast cancer progression, specifically in later stages of the disease.
This paper represents the first study on Bax G(−245)A polymorphism in breast cancer and gives an opinion about the possible effects of this polymorphism in breast cancer progression. However further validations in larger studies are needed to clarify the role of G(−248)A polymorphism in breast cancer.
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